Cited by 434Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Mahaffey, Kenneth W., Wojdyla, Daniel M., Carroll, Kevin, Becker, Richard C., Storey, Robert F., Angiolillo, Dominick J., Held, Claes, Cannon, Christopher P., James, Stefan, Pieper, Karen S., Horrow, Jay, Harrington, Robert A., Wallentin, Lars·2011·Circulation

DOI 10.1161/circulationaha.111.047498

Open this paper in CoChat — free account

Abstract

Background—: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, a prespecified subgroup analysis showed a significant interaction between treatment and region ( P =0.045), with less effect of ticagrelor in North America than in the rest of the world. Methods and Results—: Reasons for the interaction were explored independently by 2 statistical groups. Systematic errors in trial conduct were investigated. Statistical approaches evaluated the likelihood of play of chance. Cox regression analyses were performed to quantify how much of the regional interaction could be explained by patient characteristics and concomitant treatments, including aspirin maintenance therapy. Landmark Cox regressions at 8 time points evaluated the association of selected factors, including aspirin dose, with outcomes by treatment. Systematic errors in trial conduct were ruled out. Given the large number of subgroup analyses performed and that a result numerically favoring clopidogrel in at least 1 of the 4 prespecified regions could occur with 32% probability, chance alone cannot be ruled out. More patients in the United States (53.6%) than in the rest of the world (1.7%) took a median aspirin dose ≥300 mg/d. Of 37 baseline and postrandomization factors explored, only aspirin dose explained a substantial fraction of the regional interaction. In adjusted analyses, both Cox regression with median maintenance dose and landmark techniques showed that, in patients taking low-dose maintenance aspirin, ticagrelor was associated with better outcomes compared with clopidogrel, with statistical superiority in the rest of the world and similar outcomes in the US cohort. Conclusions—: The regional interaction could arise from chance alone. Results of 2 independently performed analyses identified an underlying statistical interaction with aspirin maintenance dose as a possible explanation for the regional difference. The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00391872.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.047498

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation
Authors Task Force Members, de Werf, F. V., Bax, J. J., Betriu, A., Blomström‐Lundqvist, C., Crea, F., Falk, V., Filippatos, G. S., Fox, K. A. A., Huber, K., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn416 · Cited by 2,309
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,972
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
Bassand, J., Hamm, C. W., Ardissino, D., Boersma, E. H., Budaj, A., Fernández‐Avilés, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L. C., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,860
Self-citation
Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction
Lee, K. L., Woodlief, L. H., Topol, E. J., Weaver, W. D., Betriu, A., Col, J. J., Simoons, M. L., Aylward, P. E., de Werf, F. V., & Califf, R. M. (1995) · Circulation · doi:10.1161/01.cir.91.6.1659 · Cited by 1,093
Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation
Boersma, E. H., Pieper, K. S., Steyerberg, E. W., Wilcox, R. G., Chang, W.-C., Lee, K. L., Akkerhuis, K. M., Harrington, R. A., Deckers, J. W., Armstrong, P. W., et al. (2000) · Circulation · doi:10.1161/01.cir.101.22.2557 · Cited by 962
Self-citation
Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
The CURRENT–OASIS 7 Investigators (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909475 · Cited by 767
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
FitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & BRASH, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 662
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
Cannon, C. P., Husted, S., Harrington, R. A., Scirica, B. M., Emanuelsson, H., Peters, G. R., & Storey, R. F. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.053 · Cited by 496
Self-citation
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
James, S. K., Åkerblom, A., Cannon, C. P., Emanuelsson, H., Husted, S., Katus, H. A., Skene, A. M., Steg, P. G., Storey, R. F., Harrington, R. A., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.01.003 · Cited by 404
Self-citation

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 1

Wallentin L Becker RC Budaj A Cannon CP Emanuelsson H Held C Horrow J Husted S James S Katus H Mahaffey KW Scirica BM Skene A Steg PG Storey RF Harrington RA; PLATO Investigators Freij A Thorsén M . Ticagrelor versus clopidogrel in patients with acute coronary syndromes [supplement]. N Engl J Med. 2009;361:1045–1057 e1–e34. http://www.nejm.org/doi/suppl/10.1056/NEJMoa0904327/suppl_file/nejm_wallentin_1045sa1.pdf. Accessed June 10 2011. · DOI · Paper page

Sorted by citations

Items 101–200 of 434

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry
Basra, S. S., Wang, T. Y., Simon, D. N., Chiswell, K., Virani, S. S., Alam, M., Nambi, V., Denktas, A. E., Deswal, A. M., Bozkurt, B., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008125 · Cited by 38
Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis
Haller, P. M., Sulzgruber, P., Kaufmann, C. C., Geelhoed, B., Tamargo, J. L., Waßmann, S., Schnabel, R. B., Westermann, D., Huber, K., Niessner, A., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz021 · Cited by 41
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC)
Navarese, E. P., Landi, A., Oliva, A., Piccolo, R., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Fox, K. A. A., Halvorsen, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad016 · Cited by 37
Self-citation
Economic Analysis of Ticagrelor Therapy From a U.S. Perspective
Cowper, P. A., Pan, W., Anstrom, K. J., Kaul, P., Wallentin, L. C., Davidson-Ray, L. D., Nikolic, E., Janzon, M., Levin, L., Cannon, C. P., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.11.034 · Cited by 36
Self-citation
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome
Parker, W. A., Orme, R. C., Hanson, J., Stokes, H. M., Bridge, C. M., Shaw, P. A., Sumaya, W., Thorneycroft, K., Petrucci, G., Porro, B., et al. (2019) · Platelets · doi:10.1080/09537104.2019.1572880 · Cited by 36
Self-citation
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54
Parker, W. A., & Storey, R. F. (2016) · Heart · doi:10.1136/heartjnl-2015-307858 · Cited by 35
Self-citation
An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment
Fanaroff, A. C., Li, S., Webb, L. E., Miller, V., Návar, A. M., Peterson, E. D., & Wang, T. Y. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004675 · Cited by 35
The Platelet P2 Receptors
Cattaneo, M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00014-6 · Cited by 35
Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel‐Hyporesponsive Patients
Barra, M. E., Berger, K., Tesoro, E. P., & Brophy, G. M. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2228 · Cited by 34
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany
Theidel, U., Asseburg, C., Giannitsis, E., & Katus, H. A. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0552-7 · Cited by 34
Contemporary Patterns of Discharge Aspirin Dosing After Acute Myocardial Infarction in the United States
Hall, H. M., de Lemos, J. A., Enriquez, J. R., McGuire, D. K., Peng, S. A., Alexander, K. P., Roe, M. T., Desai, N. R., Wiviott, S. D., & Das, S. R. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000822 · Cited by 33
A review of the effects of ticagrelor on adenosine concentration and its clinical significance
Akkaif, M. A., Ng, M. L., Kader, M. A. S. A., Daud, N. A. A., Sha’aban, A., & Ibrahim, B. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00309-0 · Cited by 33
Ticagrelor: A Review of Its Use in Adults with Acute Coronary Syndromes
Dhillon, S. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0108-5 · Cited by 34
Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel
Kohli, P., Udell, J. A., Murphy, S. A., Cannon, C. P., Antman, E. M., D, E. B. M., & Wiviott, S. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.023 · Cited by 32
Self-citation
Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention
Kohli, P., Whelton, S. P., Hsu, S., Yancy, C. W., Stone, N. J., Chrispin, J., Gilotra, N. A., Houston, B. A., Ashen, M. D., Martin, S. S., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001098 · Cited by 32
Trends in characteristics of cardiovascular clinical trials 2001-2012
Butler, J., Tahhan, A. S., Georgiopoulou, V. V., Kelkar, A. A., Lee, M., Khan, B., Peterson, E. D., Fonarow, G. C., Kalogeropoulos, A. P., & Gheorghiade, M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.05.006 · Cited by 32
P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting
Zoheir, N., Elhamid, S. A., Abulata, N. N., Elsobky, M. S., Khafagy, D., & Mostafa, A. H. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32835e98bf · Cited by 31
Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease
Chirkov, Y. Y., Nguyen, T. H. T., & Horowitz, J. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031042 · Cited by 33
Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial)
Metra, M., Mentz, R. J., Hernandez, A. F., Heizer, G., Armstrong, P. W., Clausell, N., Corbalán, R., Costanzo, M. R., Dickstein, K., Dunlap, M. E., et al. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.002 · Cited by 31
Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry
Head, S. J., Parasca, C. A., Mack, M. J., Mohr, F. W., Morice, M., Holmes, D. R., Feldman, T. E., Dawkins, K. D., Colombo, A., Serruys, P. W. J. C., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu197 · Cited by 29
Thienopyridines and Other ADP-Receptor Antagonists
Bernlochner, I., & Sibbing, D. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-29423-5_7 · Cited by 29
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
Johnson, T., Baos, S., Collett, L., Hutchinson, J. L., Nkau, M., Molina, M., Aungraheeta, R., Reilly‐Stitt, C., Bowles, R., Reeves, B. C., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016495 · Cited by 27
Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
Thakkar, A., Agarwala, A., & Michos, E. D. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.24 · Cited by 30
P2Y12 receptor: platelet thrombus formation and medical interventions
Moheimani, F., & Jackson, D. E. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1188-5 · Cited by 26
Rationale of the FIBROTARGETS Study Designed to Identify Novel Biomarkers of Myocardial Fibrosis
Ferreira, J. P., Machu, J., Girerd, N., Jaisser, F., Thum, T., Butler, J., González, A., Dı́ez, J., Heymans, S. R. B., McDonald, K., et al. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12218 · Cited by 26
Aspirin Use in Heart Failure
Bermingham, M., Shanahan, M. K., O’Connell, E., Dawkins, I. R., Miwa, S., O’Hanlon, R., Gilmer, J. F., McDonald, K., & Ledwidge, M. T. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000132 · Cited by 26
High-Dose, but Not Low-Dose, Aspirin Impairs Anticontractile Effect of Ticagrelor following ADP Stimulation in Rat Tail Artery Smooth Muscle Cells
Grześk, G., Koziński, M., Tantry, U. S., Wiciński, M., Fabiszak, T., Navarese, E. P., Grześk, E., Jeong, Y., Gurbel, P. A., & Kubica, J. (2013) · BioMed Research International · doi:10.1155/2013/928271 · Cited by 26
Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings
Birnbaum, G. D., Birnbaum, I., Ye, Y., & Birnbaum, Y. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6615-4 · Cited by 25
A critical overview on ticagrelor in acute coronary syndromes
Navarese, E. P., Buffon, A., Koziński, M., Obońska, K., Rychter, M., Kunadian, V., Austin, D., Servi, S. D., Sukiennik, A., & Kubica, J. (2012) · QJM · doi:10.1093/qjmed/hcs187 · Cited by 24
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective
Ct, C., Mellström, C., Chua, T., & Matchar, D. B. (2013) · Singapore Medical Journal · doi:10.11622/smedj.2013045 · Cited by 25
Ticagrelor: a P2Y12antagonist for use in acute coronary syndromes
Wijeyeratne, Y. D., Joshi, R., & Heptinstall, S. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.17 · Cited by 25
Critical appraisal of ticagrelor in the management of acute coronary syndrome
Nawarskas, J. J., & Snowden (2011) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s19835 · Cited by 23
Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators
Butler, J., Fonarow, G. C., O’Connor, C. M., Adams, K. F., Bonow, R. O., Cody, R. J., Collins, S. P., Dunnmon, P. M., Dinh, W., Fiuzat, M., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.12.001 · Cited by 22
Modern Management of Acute Myocardial Infarction
Welch, T. D., Yang, E. H., Reeder, G. S., & Gersh, B. J. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.03.002 · Cited by 24
Switching antiplatelet regimens: Alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: A review of the literature and practical considerations for the interventional cardiologist
Azmoon, S., & Angiolillo, D. J. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.24480 · Cited by 22
Self-citation
The Year in Atherothrombosis
Sanz, J., Moreno, P., & Fuster, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.045 · Cited by 22
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis
Nicolas, J., Dangas, G., Chiarito, M., Pivato, C. A., Spirito, A., Cao, D., Giustino, G., Beerkens, F., Camaj, A., Vogel, B., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac071 · Cited by 22
Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Tricoci, P., Lokhnygina, Y. V., Huang, Z., de Werf, F. V., Cornel, J. H., Chen, E., Wallentin, L. C., Held, C., Aylward, P. E., Moliterno, D. J., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.09.002 · Cited by 21
Self-citation
Clopidogrel “resistance”: Pre- vs post-receptor determinants
Hurst, N. L., Nooney, V. B., Raman, B., Chirkov, Y. Y., Caterina, R. D., & Horowitz, J. D. (2013) · Vascular Pharmacology · doi:10.1016/j.vph.2013.10.002 · Cited by 21
Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass grafting†
Milojevic, M., Head, S. J., Mack, M. J., Mohr, F. W., Morice, M., Dawkins, K. D., Holmes, D. R., Serruys, P. W. J. C., & Kappetein, A. P. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx104 · Cited by 21
Ticagrelor: the first novel reversible P2Y12inhibitor
Htun, W. W., & Steinhubl, S. R. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.757303 · Cited by 22
Statistical Evaluation and Analysis of Regional Interactions: The PLATO Trial Case Study
Carroll, K. J., & Fleming, T. R. (2013) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2013.783878 · Cited by 21
Self-citation
Perioperative management of antiplatelet therapy in patients with drug-eluting stents.
Dimitrova, G. T., Tulman, D. B., & Bergese, S. D. (2012) · Europe PMC (PubMed Central) · Cited by 20
Update on the Guidelines for the Management of ST-Elevation Myocardial Infarction
Levisman, J. M., & Price, M. J. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.002 · Cited by 20
Updates and Current Recommendations for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice
Cayla, G., Silvain, J., Collet, J., & Montalescot, G. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.003 · Cited by 20
The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation
Califf, R. M., Filerman, G. L., Murray, R. K., & Rosenblatt, M. (2012) · NAM Perspectives · doi:10.31478/201204d · Cited by 20
Comparative Review of Oral P2Y12 Inhibitors.
Koski, R. R., & Kennedy, B. (2018) · Europe PMC (PubMed Central) · Cited by 20
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor
Triska, J., Maitra, N. S., Deshotels, M. R., Haddadin, F. I., Angiolillo, D. J., Vilahur, G., Jneid, H. M., Atar, D., & Birnbaum, Y. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07373-5 · Cited by 19
Self-citation
Review of the Ticagrelor Trials Evidence Base
Herron, G. C., & Bates, E. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031606 · Cited by 21
Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)
Mahaffey, K. W., Huang, Z., Wallentin, L. C., Storey, R. F., Jennings, L. K., Tricoci, P., White, H. D., Armstrong, P. W., Aylward, P. E., Moliterno, D. J., et al. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.052 · Cited by 19
Self-citation
Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions
Dunn, S. P., Holmes, D. R., & Moliterno, D. J. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.10.005 · Cited by 19
Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy
Clark, M. G., Beavers, C. J., & Osborne, J. (2015) · Heart & Lung · doi:10.1016/j.hrtlng.2014.11.005 · Cited by 20
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Serebruany, V. L., Tomek, A., Pya, Y., Bekbossynova, M. S., & Kim, M. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.125 · Cited by 19
Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes
DiNicolantonio, J. J., & Serebruany, V. L. (2013) · Diabetes · doi:10.2337/db12-0746 · Cited by 18
Dual Antiplatelet Therapy with Prasugrel or Ticagrelor Versus Clopidogrel in Interventional Cardiology
Clemmensen, P. M., Dridi, N. P., & Holmvang, L. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6444-2 · Cited by 18
Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes
Thomas, M. R., & Storey, R. F. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9524-6 · Cited by 18
Self-citation
Treatment of acute coronary syndrome
Trost, J. C., & Lange, R. A. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31824e18c2 · Cited by 18
Commentary: On the levels of patient selection in registry-based randomized controlled trials
Lasch, F., Weber, K., & Koch, A. (2019) · Trials · doi:10.1186/s13063-019-3214-x · Cited by 18
New antiplatelet agents in the treatment of acute coronary syndromes
Sabouret, P. F., & Taiel-Sartral, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.01.009 · Cited by 17
Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
Berger, J. S. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0291-2 · Cited by 17
Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis
Liu, E., Hsueh, L., Kim, H., & Vidovich, M. I. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.09.003 · Cited by 17
Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS)
Sandner, S. E., Gaudino, M. F. L., Agewall, S., Bonalumi, G., Bonaros, N. E., Czerny, M., Jeppsson, A., Milojevic, M., Niessner, A., Parolari, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf423 · Cited by 18
The underutilisation of dual antiplatelet therapy in acute coronary syndrome
Anastasius, M. O., Lau, J. K., Hyun, K. K., D'Souza, M. I., Patel, A. A., Rankin, J. M., Walters, D., Juergens, C., Aliprandi‐Costa, B., Yan, A. T.-K., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.04.077 · Cited by 16
Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model
Ni, R., Vaezzadeh, N., Zhou, J., Weitz, J. I., Cattaneo, M., & Gross, P. L. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311404 · Cited by 16
Acute Coronary Syndromes
Basra, S. S., Virani, S. S., Paniagua, D. E., Kar, B., & Jneid, H. M. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.004 · Cited by 16
Profiling the eicosanoid networks that underlie the anti‐ and pro‐thrombotic effects of aspirin
Crescente, M., Armstrong, P. C. J., Kirkby, N. S., Edin, M. L., Chan, M. V., Lih, F. B., Jiao, J., Maffucci, T., Allan, H. E., Mein, C. A., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000312r · Cited by 16
Acute Coronary Syndrome: Focus on Antiplatelet Therapy
Bobadilla, R. V. (2016) · Critical Care Nurse · doi:10.4037/ccn2016497 · Cited by 15
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
Angiolillo, D. J., Cho, J. R., Rollini, F., Franchi, F., & Ferrante, E. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s36045 · Cited by 15
Self-citation
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases
Tao, L., Ren, S., Zhang, L., Liu, W., Zhao, Y., Chen, C., Mao, X., Chen, Z., & Gu, X. (2022) · Medical Science Monitor · doi:10.12659/msm.935664 · Cited by 16
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
Kumar, A., Lutsey, P. L., Peter, W. L. S., Schommer, J. C., Hof, J. V., Rajpurohit, A., & Farley, J. F. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2797 · Cited by 15
Emerging Antiplatelet Therapy for Coronary Artery Disease and Acute Coronary Syndrome
Packard, K. A., Campbell, J. A., Knezevich, J. T., & Davis, E. M. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01021.x · Cited by 15
Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges
Zannad, F. M., Crea, F., Keaney, J. F., Spencer, S., Hill, J. A., Pfeffer, M. A., Pocock, S., Raderschadt, E., Ross, J. S., Sacks, C. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad279 · Cited by 14
Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non–Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients
Winkelmayer, W. C., Arnold, S., Burke, S. K., Chertow, G. M., Eckardt, K., Jardine, A. G., Lewis, E. F., Luo, W. F., Matsushita, K., McCullough, P. A., et al. (2023) · Kidney Medicine · doi:10.1016/j.xkme.2023.100666 · Cited by 15
Percutaneous Coronary Intervention
Khera, S., Kolte, D. S., & Bhatt, D. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00016-4 · Cited by 14
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition
Björkman, J., Zachrisson, H., Forsberg, G., von Bahr, H., Hansson, G. I., Warner, T. D., & Nylander, S. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.01.029 · Cited by 14
Example-based illustrations of design, conduct, analysis and result interpretation of multi-regional clinical trials
Quan, H., Mao, X., Tanaka, Y., Binkowitz, B. S., Li, G., Chen, J., Zhang, J., Zhao, P.-L., Ouyang, S. P., & Chang, M. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.04.009 · Cited by 14
Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS
Badjatiya, A., & Rao, S. V. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1090-3 · Cited by 15
Aspirin does not Reduce the Clinical Benefits of the Mineralocorticoid Receptor Antagonist Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms: An Analysis of the EMPHASIS-HF Study
Chin, K. L., Collier, T. J., Pitt, B., McMurray, J. J. V., Swedberg, K. B., van Veldhuisen, D. J., Pocock, S., Vincent, J., Turgonyi, E., Zannad, F. M., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.485 · Cited by 13
Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
Traby, L., Kollars, M., Kaider, A., Siller-Matula, J. M., Wolkersdorfer, M. F., Wolzt, M., Kyrle, P. A., & Eichinger, S. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1616 · Cited by 12
Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population
Chatterjee, S., Fanaroff, A. C., Parzynski, C. S., Curtis, J. P., Kolansky, D. M., Maddox, T. M., Mukherjee, D., Yeh, R. W., & Giri, J. S. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.08.047 · Cited by 14
Ticagrelor Use in a Patient With a Documented Clopidogrel Hypersensitivity
Harris, J. R., & Coons, J. C. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014539143 · Cited by 13
Selection of P2Y 12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
Tantry, U. S., Navarese, E. P., Myat, A., & Gurbel, P. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.01.003 · Cited by 13
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome
Wallentin, L. C., Becker, R. C., Cannon, C. P., Held, C., Himmelmänn, A., Husted, S., James, S. K., Katus, H. A., Mahaffey, K. W., Pieper, K. S., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.003 · Cited by 13
Self-citation
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., Price, M. J., Prats, J., Deliargyris, E. N., Mahaffey, K. W., et al. (2016) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.116.003612 · Cited by 12
Self-citation
A comprehensive comparative review of adenosine diphosphate receptor antagonists
Oh, E., Abraham, T., Saad, N., Rapp, J. A., Vastey, F., & Balmir, E. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.647683 · Cited by 12
ADP Receptor Antagonists
Cattaneo, M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00054-7 · Cited by 12
Targeting ticagrelor: a novel therapy for emergency reversal
Cave, B. E., Rawal, A., Ardeshna, D. R., Ibebuogu, U. N., Sai‐Sudhakar, C., & Khouzam, R. N. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.08 · Cited by 12
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus
Calderone, D., Capodanno, D., & Angiolillo, D. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1792293 · Cited by 12
Self-citation
Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Serebruany, V. L., Tanguay, J., Benavides, M. A., Cabrera-Fuentes, H. A., Eisert, W. G., Kim, M. H., Yoon, J., Lee, C. W., Jang, K., Swan, J., et al. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001286 · Cited by 12
Multicenter Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_21 · Cited by 13
Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy
Good, R., McGarrity, A. M., Sheehan, R., James, T. E., Miller, H., Stephens, J. C., Watkins, S., McConnachie, A., Goodall, A. H., & Oldroyd, K. G. (2014) · Platelets · doi:10.3109/09537104.2013.870334 · Cited by 12
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes
Lip, G. Y. H., & Huber, K. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0453 · Cited by 12
New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications
Procter, N. E. K., Hurst, N. L., Nooney, V. B., Imam, H., Caterina, R. D., Chirkov, Y. Y., & Horowitz, J. D. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6671-4 · Cited by 11
Using Machine Learning to Identify Heterogeneous Effects in Randomized Clinical Trials—Moving Beyond the Forest Plot and Into the Forest
Goldstein, B. A., & Rigdon, J. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0004 · Cited by 11
Cardiovascular Pharmacology Core Reviews
Gaglia, M. A., & Clavijo, L. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413503043 · Cited by 12
An evidence-based review of current anti-platelet options for STEMI patients
Cayla, G., Silvain, J., O’Connor, S. A., Collet, J., & Montalescot, G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.04.160 · Cited by 11
Bleeding associated with the management of acute coronary syndromes
Silva, K. D., Myat, A., Cotton, J. M., James, S. K., Gershlick, A., & Stone, G. W. (2017) · Heart · doi:10.1136/heartjnl-2015-307602 · Cited by 11
Self-citation
Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial
Sandner, S. E., Schunkert, H., Kastrati, A., Wiedemann, D., Misfeld, M., Böning, A., Tebbe, U., Nowak, B., Stritzke, J., Laufer, G., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz313 · Cited by 11
Importance of potent P2Y12receptor blockade in acute myocardial infarction: focus on prasugrel
Jeong, Y., Tantry, U. S., & Gurbel, P. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.704909 · Cited by 10
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark
Thrane, P. G., Olesen, K. K. W., Würtz, M., Gyldenkerne, C., Madsen, M., Jensen, L. O., Raungaard, B., Sørensen, H. T., Thim, T., Kristensen, S. D., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100301 · Cited by 10

Authors: Mahaffey, K. W., Wojdyla, D. M., Carroll, K., Becker, R. C., Storey, R. F., Angiolillo, D. J., Held, C., Cannon, C. P., James, S., Pieper, K. S., Horrow, J., Harrington, R. A., & Wallentin, L.
Affiliations: Uppsala University (SE)
ORCID: Mahaffey, Kenneth W.
Wojdyla, Daniel M.
Carroll, Kevin
Becker, Richard C.
Storey, Robert F.
Angiolillo, Dominick J.
Held, Claes
Cannon, Christopher P.
James, Stefan
Pieper, Karen S.
Horrow, Jay
Harrington, Robert A.
Wallentin, Lars
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-08-02
Volume: 124
Issue: 5
Pages: 544-554
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.111.047498
OpenAlex: W2085260510
Cited by: 434
References: 20
Citations by year: 2026: 2 · 2025: 11 · 2024: 10 · 2023: 13 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 29 · 2018: 20 · 2017: 32 · 2016: 37 · 2015: 38 · 2014: 52 · 2013: 55 · 2012: 68
FWCI: 40.98
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Duke Clinical Research Institute
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: ticagrelor, clopidogrel, PLATO trial, regional interaction, platelet aggregation inhibition, antiplatelet therapy, cardiovascular mortality, myocardial infarction, stroke, subgroup analysis
MeSH terms: Clopidogrel, Ticagrelor, Adenosine, Aged, Aspirin, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Risk Factors, Ticlopidine, United States, Global Health, Proportional Hazards Models, Stroke, Purinergic P2Y Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks